Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XP-3924
- Development stage
- Phase 2
- Lead developer
- Xeris Biopharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
**XP-3924** is an investigational, fixed-ratio **XeriSol** co-formulation of pramlintide and regular human insulin developed by Xeris for mealtime glycemic control in **type 1 diabetes mellitus**. It combines pramlintide, an amylin analog that slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety, with insulin human, which activates the insulin receptor to lower blood glucose. In a completed randomized Phase 2 crossover study, a single subcutaneous pre-meal dose reduced post-challenge hyperglycemia relative to regular insulin alone while providing glycemic control comparable to separately injected pramlintide plus regular insulin.
- Other names
- pramlintide + regular insulin
02
Targets
AMY receptor (Calcitonin receptor (with ramps))INSR (Insulin receptor)
Beyond the preview
Go deeper on XP-3924.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XP-3924.